Auteurs

David Mulder

Counsel

Read More

Christian Dekoninck

Associé

Read More

Adrian Toutoungi

Associé

Read More

Dr. Anja Lunze, LL.M.

Partner

Read More

Dr. Angela Knierim

Salary Partner

Read More
Auteurs

David Mulder

Counsel

Read More

Christian Dekoninck

Associé

Read More

Adrian Toutoungi

Associé

Read More

Dr. Anja Lunze, LL.M.

Partner

Read More

Dr. Angela Knierim

Salary Partner

Read More

23 novembre 2020

Pharmaceutical patent law – 2 de 2 Publications

Pharmaceutical patent law in times of crisis: A comparative study – Part 2

  • Quick read

Which extraordinary regulations have been put in place for speeding up clinical trials in emergency situations like the current coronavirus pandemic? And how is early access to new medicines warranted under such circumstance?

The second part of the two-part series ‘Pharmaceutical Patent Law in Times of Crisis: A Comparative Study’, written for the European Intellectual Property Review by our international team, addresses these questions and more on both a broad, European level and from the perspective of six national jurisdictions.
 

Read the article here

Dans cette série

Brevets et innovation

Pharmaceutical patent law in times of crisis: A comparative study – Part 1

9 November 2020

par plusieurs auteurs

Brevets et innovation

Pharmaceutical patent law in times of crisis: A comparative study – Part 2

23 November 2020

par plusieurs auteurs

Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

Sciences de la vie et Santé

Biotech acquisition trend: radiopharmaceuticals

8 mai 2024
Briefing

par Adrian Toutoungi

Cliquer ici pour en savoir plus
Sciences de la vie et Santé

Early IP Strategy for Life Sciences Start-Ups Pays off

We explain the 5 biggest pitfalls

22 mars 2024
Briefing

par Dr. Anja Lunze, LL.M. et Tobias Baus, LL.M., Dipl.-Ing.

Cliquer ici pour en savoir plus
Dispositifs médicaux

Artificial Intelligence (AI) in medical devices: The better the product, the harder the conformity assessment?

27 octobre 2023
Briefing

par Dr. Angela Knierim

Cliquer ici pour en savoir plus